Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

SWTX

SpringWorks Therapeutics (SWTX)

SpringWorks Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SWTX
DateHeureSourceTitreSymboleSociété
07/06/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SWTXSpringWorks Therapeutics Inc
05/06/202422h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
05/06/202413h00GlobeNewswire Inc.SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:SWTXSpringWorks Therapeutics Inc
03/06/202422h37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
23/05/202423h13GlobeNewswire Inc.SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:SWTXSpringWorks Therapeutics Inc
08/05/202413h00GlobeNewswire Inc.SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care ConferenceNASDAQ:SWTXSpringWorks Therapeutics Inc
02/05/202412h30GlobeNewswire Inc.SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business UpdatesNASDAQ:SWTXSpringWorks Therapeutics Inc
24/04/202419h31GlobeNewswire Inc.SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:SWTXSpringWorks Therapeutics Inc
18/04/202413h00GlobeNewswire Inc.SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024NASDAQ:SWTXSpringWorks Therapeutics Inc
04/03/202412h30GlobeNewswire Inc.SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PNNASDAQ:SWTXSpringWorks Therapeutics Inc
29/02/202414h30GlobeNewswire Inc.SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid TumorsNASDAQ:SWTXSpringWorks Therapeutics Inc
27/02/202414h23Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SWTXSpringWorks Therapeutics Inc
27/02/202413h29Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SWTXSpringWorks Therapeutics Inc
27/02/202412h51Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SWTXSpringWorks Therapeutics Inc
27/02/202412h30GlobeNewswire Inc.SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business UpdatesNASDAQ:SWTXSpringWorks Therapeutics Inc
22/02/202413h00GlobeNewswire Inc.SpringWorks Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:SWTXSpringWorks Therapeutics Inc
14/02/202414h56Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SWTXSpringWorks Therapeutics Inc
31/01/202413h00GlobeNewswire Inc.SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:SWTXSpringWorks Therapeutics Inc
08/01/202412h30GlobeNewswire Inc.SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SWTXSpringWorks Therapeutics Inc
21/12/202313h00GlobeNewswire Inc.SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SWTXSpringWorks Therapeutics Inc
08/12/202322h05GlobeNewswire Inc.SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:SWTXSpringWorks Therapeutics Inc
05/12/202306h32GlobeNewswire Inc.SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common StockNASDAQ:SWTXSpringWorks Therapeutics Inc
04/12/202322h13GlobeNewswire Inc.SpringWorks Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:SWTXSpringWorks Therapeutics Inc
29/11/202313h00GlobeNewswire Inc.SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:SWTXSpringWorks Therapeutics Inc
28/11/202313h53Dow Jones NewsSpringWorks Shares Rise on FDA Approval for Tumor TreatmentNASDAQ:SWTXSpringWorks Therapeutics Inc
28/11/202300h46Dow Jones NewsSpringWorks Gets FDA Approval for Desmoid Tumor TreatmentNASDAQ:SWTXSpringWorks Therapeutics Inc
28/11/202300h04GlobeNewswire Inc.SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid TumorsNASDAQ:SWTXSpringWorks Therapeutics Inc
16/11/202312h30GlobeNewswire Inc.SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PNNASDAQ:SWTXSpringWorks Therapeutics Inc
02/11/202312h54Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:SWTXSpringWorks Therapeutics Inc
02/11/202311h38Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SWTXSpringWorks Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SWTX